COVID-19 and community self-prescribing: a dangerous folly.
作者信息
Donnelly Seamas C
机构信息
Editor-in-Chief, QJM.
出版信息
QJM. 2021 Nov 5;114(8):539. doi: 10.1093/qjmed/hcab255.
Abstract
摘要
相似文献
1
COVID-19 and community self-prescribing: a dangerous folly.2019冠状病毒病与社区自行开药：一种危险的蠢行。
QJM. 2021 Nov 5;114(8):539. doi: 10.1093/qjmed/hcab255.
2
Impact of COVID-19 on corticosteroids and antibiotics prescribing in England: an interrupted time series analysis.COVID-19 对英格兰皮质类固醇和抗生素处方的影响：一项中断时间序列分析。
J Public Health (Oxf). 2021 Sep 22;43(3):517-520. doi: 10.1093/pubmed/fdab017.
3
Prescribing COVID-19 treatments: what we should never forget.开具新冠治疗药物：我们绝不能忘记的事。
J Infect. 2020 Aug;81(2):e85. doi: 10.1016/j.jinf.2020.05.018. Epub 2020 May 13.
4
[Recommendations for the study and pharmacological management in adult patients with suspected infection by SARS-CoV-2 (COVID-19)].[关于疑似感染严重急性呼吸综合征冠状病毒2（COVID-19）成年患者的研究及药物治疗建议]
Rev Chilena Infectol. 2020 Dec;37(6):646-666. doi: 10.4067/S0716-10182020000600646.
5
Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19.皮质类固醇对新冠病毒肺炎住院患者针对严重急性呼吸综合征冠状病毒2的抗体反应及病毒清除无不良影响。
J Infect. 2021 Mar;82(3):414-451. doi: 10.1016/j.jinf.2020.10.018. Epub 2020 Oct 25.
6
Use of inhaled corticosteroids in preschool children and variability among pediatricians: a real-world analysis before and during the SARS-CoV-2 pandemic.学龄前儿童使用吸入性皮质类固醇和儿科医生之间的差异：SARS-CoV-2 大流行前后的真实世界分析。
BMC Pediatr. 2023 Apr 1;23(1):151. doi: 10.1186/s12887-023-03968-5.
7
Corticosteroids and Delayed Conversion of SARS-CoV-2 RNA Nasopharyngeal Swabs in Hospitalized Patients With COVID 19 Pneumonia.皮质类固醇与新冠肺炎肺炎住院患者严重急性呼吸综合征冠状病毒2（SARS-CoV-2）RNA鼻咽拭子的延迟转阴
Arch Bronconeumol. 2022 Apr;58:55-58. doi: 10.1016/j.arbres.2021.11.007. Epub 2021 Nov 27.
8
Inhaled corticosteroids in early COVID-19-A tale of many facets.COVID-19早期的吸入性糖皮质激素——多方面的故事
Allergy. 2021 Nov;76(11):3540-3542. doi: 10.1111/all.15041. Epub 2021 Aug 27.
9
Inhaled corticosteroid is not associated with a poor prognosis in COVID-19.吸入性皮质类固醇与 COVID-19 的不良预后无关。
Respirology. 2021 Aug;26(8):812-815. doi: 10.1111/resp.14108. Epub 2021 Jun 26.
10
Systemic corticosteroids for COVID-19.用于治疗新型冠状病毒肺炎的全身性皮质类固醇
Acad Emerg Med. 2022 Feb;29(2):252-254. doi: 10.1111/acem.14432. Epub 2022 Jan 4.
本文引用的文献
1
Successful treatment of COVID-19 with colchicine in a kidney transplant recipient.秋水仙碱成功治疗肾移植受者的新冠肺炎。
QJM. 2021 May 19;114(3):197-199. doi: 10.1093/qjmed/hcaa323.
2
Potential role of hypovitaminosis D and vitamin D supplementation during COVID-19 pandemic.维生素 D 缺乏症和维生素 D 补充在 COVID-19 大流行期间的潜在作用。
QJM. 2021 Feb 18;114(1):3-10. doi: 10.1093/qjmed/hcaa234.
3
Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study.托珠单抗治疗重症 COVID-19 患者的结局：一项病例对照研究。
QJM. 2020 Aug 1;113(8):546-550. doi: 10.1093/qjmed/hcaa206.
4
Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients.氢气（XEN）吸入可改善哮喘和 COPD 患者的气道炎症。
QJM. 2020 Dec 1;113(12):870-875. doi: 10.1093/qjmed/hcaa164.
5
Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report.托珠单抗与氯喹联合治疗重症新型冠状病毒肺炎：一例病例报告
QJM. 2020 Aug 1;113(8):569-572. doi: 10.1093/qjmed/hcaa153.
6
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.纤溶酶原可改善 COVID-19 患者的肺部病变和低氧血症。
QJM. 2020 Aug 1;113(8):539-545. doi: 10.1093/qjmed/hcaa121.
Zotero 插件